Valuation: CSL Limited

Market Cap 60.7B 52.93B 49.85B 45.4B 85.11B 5,815B 85.22B 597B 230B 2,962B 228B 223B 9,559B P/E 2027 *
20.9x
P/E 2028 * 18.9x
Enterprise Value 69.88B 60.93B 57.38B 52.26B 97.98B 6,695B 98.1B 687B 265B 3,410B 262B 257B 11,005B EV / Sales 2027 *
4.43x
EV / Sales 2028 * 4.26x
Free-Float
99.97%
Yield 2027 *
2.37%
Yield 2028 * 2.51%
1 day+1.54%
1 week+6.70%
Current month+3.92%
1 month+4.15%
3 months+53.28%
6 months+28.74%
Current year+3.27%
1 week 171.29
Extreme 171.29
178.48
1 month 165.79
Extreme 165.79
178.48
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
222.47
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Operating Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 02/02/2011
Director/Board Member 71 09/12/2019
Date Insider Type Main position Quantity % Market Cap. Importance
26/8/26 Free

Director

523 0.0001%
26/8/26 Free 317 0.0001% -
26/8/26 Free

Director

1,586 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+1.54%+6.70%-10.12%-32.11% 59.78B
+1.56%+0.13%+33.42%-3.48% 78.37B
+8.09%+14.14%+530.37%+67.04% 61.5B
+0.29%-0.92%-10.95%+26.82% 46.53B
+1.92%+0.76%+2.71%+154.99% 45.5B
+2.57%+1.67%+57.10%-14.66% 31.84B
+0.54%+3.16%+48.77%+114.33% 25.4B
+6.00%+9.46%+11.24%+166.67% 21.43B
-0.76%-1.03%+57.53%+103.49% 15.77B
-0.71%-9.05%+27.73%+144.09% 13.02B
Average +2.10%+0.75%+74.78%+72.72% 39.92B
Weighted average by Cap. +2.54%+1.35%+97.23%+49.48%

Financials

2027 *2028 *
Net sales 15.77B 13.75B 12.95B 11.79B 22.11B 1,510B 22.13B 155B 59.76B 769B 59.22B 57.91B 2,483B 16.31B 14.22B 13.39B 12.2B 22.87B 1,563B 22.9B 160B 61.83B 796B 61.27B 59.91B 2,569B
Net income 2.82B 2.46B 2.32B 2.11B 3.96B 270B 3.96B 27.77B 10.7B 138B 10.61B 10.37B 445B 3.16B 2.75B 2.59B 2.36B 4.43B 303B 4.43B 31.07B 11.97B 154B 11.87B 11.6B 497B
Net Debt 9.18B 8B 7.54B 6.86B 12.87B 879B 12.88B 90.25B 34.78B 448B 34.47B 33.71B 1,445B 8.86B 7.72B 7.27B 6.62B 12.42B 848B 12.43B 87.09B 33.57B 432B 33.26B 32.53B 1,395B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
21/09/26 $178.30 +1.54% 811,896
18/09/26 $175.59 -1.11% 4,246,940
17/09/26 $177.56 +1.81% 1,984,012
16/09/26 $174.41 +0.09% 1,420,415
15/09/26 $174.26 +1.57% 1,417,850
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
126.75USD
Average target price
126.28USD
Spread / Average Target
-0.37%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!